Current disease status-Recurrent cancer Page 2 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer Posts on Medivizor

The effect of FDG-PET imaging on patients with melanoma treated with immunotherapy.

Posted by on Sep 28, 2018 in Melanoma | 0 comments

In a nutshell The study looked at the use of FDG-PET imaging to assess long-term outcomes of treatment in patients with melanoma. Researchers found that FDG-PET imaging may be useful in predicting long-term outcomes of treatment in these patients. Some background Treatment for melanoma has vastly improved in recent years. Immunotherapies have improved...

Read More

Fulvestrant compared to aromatase inhibitors in post-menopausal women with HR+ advanced breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to look at the safety and effectiveness of fulvestrant (Faslodex) compared to aromatase inhibitors in post-menopausal women with hormone receptor-positive (HR+) breast cancer. The authors found that fulvestrant was a safe and effective treatment in these patients when compared to aromatase inhibitors. Some...

Read More

Everolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study looked at the effectiveness and safety of a combination of two cancer drugs, everolimus (Afinitor) and exemestane (Aromasin), in women after menopause with advanced breast cancer. The authors found that these drugs were safe and effective in the treatment of these women. Some background Breast cancer is...

Read More

Pembrolizumab improves stage 3 melanoma outcomes

Posted by on Jun 4, 2018 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness of pembrolizumab (Keytruda) in the treatment of patients with stage 3 melanoma who underwent surgery. Researchers suggested that this drug is associated with longer recurrence-free survival with no new side effects. Some background The use of PD-1 antibodies, such as pembrolizumab, in patients...

Read More

Comparing two targeted therapy drugs – is gefitinib safer than erlotinib?

Posted by on May 21, 2018 in Lung cancer | 0 comments

In a nutshell This study compared two targeted therapy drugs gefitinib (Iressa) and erlotinib (Tarceva) in terms of effectiveness and safety at treating patients with advanced non-small-cell lung cancer. They concluded gefitinib was as effective as erlotinib but with fewer toxic side effects. Some background Current and newer treatment options...

Read More

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Posted by on Apr 21, 2018 in Lung cancer | 0 comments

In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...

Read More

Treating types of non-small-cell lung cancer with nedaplatin chemotherapy

Posted by on Jan 17, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at the effectiveness of the chemotherapy drug nedaplatin (Aqupla) to treat specific types of non-small-cell lung cancer (NSCLC). The authors concluded that nedaplatin was effective at treating patients with squamous cell lung cancer. Some background Targeted therapy has improved the outcome of certain types of NSCLC...

Read More

Looking for patients with advanced squamous cell non-small-cell lung cancer or head and neck squamous cell carcinoma to test a new type of immunotherapy

Posted by on Dec 20, 2017 in Lung cancer | 0 comments

In a nutshell This phase 1 trial is examining the safety and effectiveness of a new type of immunotherapy. The treatment involves genetically enhancing patients’ own immune cells to better fight advanced non-small-cell lung cancer (NSCLC) or head and neck cancer. The main outcome to be measured will be the highest safe dose of the treatment. This...

Read More